SG11201908475RA - Process for making hepatitis b core protein modulators - Google Patents

Process for making hepatitis b core protein modulators

Info

Publication number
SG11201908475RA
SG11201908475RA SG11201908475RA SG11201908475RA SG 11201908475R A SG11201908475R A SG 11201908475RA SG 11201908475R A SG11201908475R A SG 11201908475RA SG 11201908475R A SG11201908475R A SG 11201908475RA
Authority
SG
Singapore
Prior art keywords
international
suite
pct
hepatitis
carmel
Prior art date
Application number
Inventor
Leping Li
Lee Arnold
Sreenivasa Reddy
Original Assignee
Assembly Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assembly Biosciences Inc filed Critical Assembly Biosciences Inc
Publication of SG11201908475RA publication Critical patent/SG11201908475RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/02—Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date ill Hu omits I El ° 01110110110111Elin 011 (10) International Publication Number WO 2018/169907 Al 20 September 2018 (20.09.2018) WIP0 I PCT (51) International Patent Classification: CO7D 417/12 (2006.01) (21) International Application Number: PCT/US2018/022100 (22) International Filing Date: 13 March 2018 (13.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/470,560 13 March 2017 (13.03.2017) US (71) Applicant: ASSEMBLY BIOSCIENCES, INC. [US/US]; 11711 N. Meridian Street, Suite 310, Cannel, IN 46032 (US). (72) Inventors: LI, Leping; 11711 N. Meridian Street, Suite 310, Carmel, IN 46032 (US). ARNOLD, Lee, D.; 3751 East Sterling Avenue, Bloomington, IN 47401 (US). REDDY, Sreenivasa; 11711 N. Meridian Street, Suite 310, Carmel, IN 46032 (US). (74) Agent: UITTO, Olivia, D. et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: PROCESS FOR MAKING HEPATITIS B CORE PROTEIN MODULATORS (57) : The present disclosure provides, in part, a process for preparing com- R 2 0 NH pounds (I) having allosteric effector properties against Hepatitis B virus Cp. R 3 1-1 N H R 7 R 4 S Y R 1 Formula R 5 (°)w R 6 C
SG11201908475R 2017-03-13 2018-03-13 Process for making hepatitis b core protein modulators SG11201908475RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762470560P 2017-03-13 2017-03-13
PCT/US2018/022100 WO2018169907A1 (en) 2017-03-13 2018-03-13 Process for making hepatitis b core protein modulators

Publications (1)

Publication Number Publication Date
SG11201908475RA true SG11201908475RA (en) 2019-10-30

Family

ID=61768549

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908475R SG11201908475RA (en) 2017-03-13 2018-03-13 Process for making hepatitis b core protein modulators

Country Status (9)

Country Link
US (2) US11040965B2 (en)
EP (1) EP3596070A1 (en)
JP (1) JP7179751B2 (en)
KR (1) KR102575605B1 (en)
CN (1) CN110612300B (en)
AU (1) AU2018236188B2 (en)
CA (1) CA3056696A1 (en)
SG (1) SG11201908475RA (en)
WO (1) WO2018169907A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109937201A (en) 2016-09-15 2019-06-25 组装生物科学股份有限公司 Hepatitis B virus regulator
CN110621672A (en) 2017-03-02 2019-12-27 组装生物科学股份有限公司 Cyclic sulfonamide compounds and methods of use thereof
CA3140103A1 (en) * 2019-05-24 2020-12-03 Assembly Biosciences, Inc. Pharmaceutical compositions for the treatment of hbv
CN111333513B (en) * 2020-04-17 2021-08-27 江苏恒沛药物科技有限公司 Preparation method of 2,4-difluoro-3-nitrobenzoic acid

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1480553A (en) 1976-06-03 1977-07-20 Pfizer Ltd Tricyclic sulphonamides
JPS58225074A (en) 1982-06-25 1983-12-27 Chugai Pharmaceut Co Ltd Dibenzoazepine derivative
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9707695D0 (en) * 1996-08-07 1997-06-04 Hoffmann La Roche Tricyclic dione derivatives
WO2005040109A1 (en) * 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE102004004928A1 (en) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
US20070105819A1 (en) 2005-10-17 2007-05-10 Roger Olsson CB-1 modulating compounds and their use
US20070105835A1 (en) 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
JP4042065B1 (en) 2006-03-10 2008-02-06 健治 吉田 Input processing system for information processing device
WO2008036139A2 (en) 2006-06-07 2008-03-27 The Regents Of The University Of California Inhibitors of mshc and homologs thereof, and methods of identifying same
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
EP2313100B1 (en) 2008-07-23 2016-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the plasmodial surface anion channel as antimalarials
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
EP2726459B1 (en) 2011-07-01 2019-09-11 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
US20150141384A1 (en) * 2012-07-03 2015-05-21 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
RU2519546C1 (en) 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") CONJUGATES AND SMALL MOLECULES, INTERACTING WITH CD16a RECEPTOR
AR095426A1 (en) 2013-03-14 2015-10-14 Onyx Therapeutics Inc TRIPEPTIDE INHIBITORS OF PROTEASA EPOXYCETONE
NZ711376A (en) 2013-03-15 2020-01-31 Sanofi Sa Heteroaryl compounds and uses thereof
AU2014281511A1 (en) 2013-06-19 2015-12-03 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
WO2015017412A1 (en) 2013-07-29 2015-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists
CN104803880B (en) * 2014-01-23 2017-11-21 广州喜鹊医药有限公司 Compound with neuroprotective effect and preparation method and application thereof
EP3116316B1 (en) 2014-03-13 2019-07-10 Indiana University Research and Technology Corporation Hepatitis b core protein allosteric modulators
BR112016028934B1 (en) 2014-06-10 2021-06-22 Basf Se COMPOUNDS, COMPOSITION, USE OF A COMPOUND OF FORMULA I AND METHOD FOR FIGHTING PHYTOPATHOGENIC FUNGI
TWI786639B (en) 2015-09-15 2022-12-11 美商艾森伯利生物科學公司 Hepatitis b core protein modulators
CN109937201A (en) * 2016-09-15 2019-06-25 组装生物科学股份有限公司 Hepatitis B virus regulator

Also Published As

Publication number Publication date
CN110612300A (en) 2019-12-24
JP7179751B2 (en) 2022-11-29
EP3596070A1 (en) 2020-01-22
AU2018236188A1 (en) 2019-10-17
AU2018236188B2 (en) 2022-01-27
US20200002325A1 (en) 2020-01-02
KR102575605B1 (en) 2023-09-05
JP2020510059A (en) 2020-04-02
US20210380577A1 (en) 2021-12-09
KR20190128675A (en) 2019-11-18
CA3056696A1 (en) 2019-09-20
WO2018169907A1 (en) 2018-09-20
CN110612300B (en) 2023-10-20
US11040965B2 (en) 2021-06-22

Similar Documents

Publication Publication Date Title
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201908012SA (en) Cyclic sulfamide compounds and methods of using same
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201901307VA (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG11201809064QA (en) Chimeric neurotoxins
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201908475RA (en) Process for making hepatitis b core protein modulators
SG11201810522UA (en) Anti-cd40 antibodies and their uses
SG11201809625RA (en) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201907023UA (en) Method of reducing neutropenia
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201805001UA (en) Method of treating influenza a
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201907774VA (en) Sulfoximine glycosidase inhibitors
SG11201809594WA (en) Nicotine particles and compositions
SG11201908091QA (en) Aqueous anti-pd-l1 antibody formulation